Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03809000 · ClinicalTrials.gov registry record · Phase 2
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
A Phase 2 study of Prostate Cancer, sponsored by RTOG Foundation.
- Active
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT03809000: Active Phase 2 study of Prostate Cancer, sponsored by RTOG Foundation.
NCT03809000 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by RTOG Foundation. The registered enrollment target is 188 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03809000, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by RTOG Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.
Primary Outcome
Progression-free survival (PFS) is estimated by the Kaplan-Meier method. PFS time is measured from randomization to the date of first PFS failure (biochemical or clinical failure, initiation of new unplanned anticancer treatment, or death from any cause) or last known follow-up (censored). Analysis was to occur after progression or death was reported for 101 participants. Biochemical failure is defined as first post-RT detectable PSA (PSA ≥ 0.05). Clinical failure is defined as either a local, r
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Enzalutamide
- DRUG Bicalutamide
- DRUG GnRH analog
Study Locations (20)
California
- Marin Cancer Care, Inc. - Greenbrae
- Marin Health Medical Center - Greenbrae
- University of Southern California - Los Angeles
- USC Medical Center - Los Angeles County - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Roseville Radiation Oncology Center - Roseville
- Sutter Roseville Medical Center - Roseville
- Sutter Medical Center Sacramento - Sacramento
- University of California, San Francisco - San Francisco
Arizona
- Arizona Center for Cancer Care - Gilbert - Gilbert
- Arizona Center for Cancer Care - Peoria - Peoria
- Arizona Center for Cancer Care - Phoenix - Phoenix
- Arizona Center for Cancer Care - Scottsdale East - Scottsdale
- Arizona Center for Cancer Care - Scottsdale North - Scottsdale
- Arizona Center for Cancer Care - Surprise - Surprise
Florida
- University of Florida Health Science Center - Gainesville
- AdventHealth Orlando - Orlando
- Moffitt Cancer Center - Tampa
Colorado
- Valley View Hospital Cancer Center - Glenwood Springs
Georgia
- Nancy N. & J.C. Lewis Cancer & Research Pavilion - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2029-09-15 |
| Phase | Phase 2 |
What the registry record for NCT03809000 still lists
NCT03809000 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT03809000 names 20 study sites across 5 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03809000 about?
NCT03809000 is a clinical study titled "A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery". Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT...
What is the current status of trial NCT03809000?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2019-04-15. Estimated completion is 2029-09-15.
What conditions does trial NCT03809000 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03809000?
The interventions under investigation include: Radiation Therapy (RADIATION), Enzalutamide (DRUG), Bicalutamide (DRUG), GnRH analog (DRUG).
Who is sponsoring clinical trial NCT03809000?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03809000 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03809000's enrollment target sits among peer trials
188 237th of 735 higher than 499 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI